These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29611475)

  • 1. Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance.
    Naghizadeh S; Mansoori B; Mohammadi A; Sakhinia E; Baradaran B
    Curr Med Chem; 2019; 26(34):6282-6303. PubMed ID: 29611475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of RNA interference in drug-resistant cancers.
    Lage H
    Future Oncol; 2009 Mar; 5(2):169-85. PubMed ID: 19284376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
    Abbasi M; Lavasanifar A; Uludag H
    Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance against cancer therapeutic drugs.
    Chatterjee S; Damle SG; Sharma AK
    Curr Pharm Biotechnol; 2014; 15(12):1105-12. PubMed ID: 25429651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
    Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
    Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
    J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference-based therapy and its delivery systems.
    Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK
    Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming multidrug resistance by RNA interference.
    Stege A; Krühn A; Lage H
    Methods Mol Biol; 2010; 596():447-65. PubMed ID: 19949936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects of RNA interference therapy for cancer.
    Pai SI; Lin YY; Macaes B; Meneshian A; Hung CF; Wu TC
    Gene Ther; 2006 Mar; 13(6):464-77. PubMed ID: 16341059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.
    Rueff J; Rodrigues AS
    Methods Mol Biol; 2016; 1395():1-18. PubMed ID: 26910065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
    Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
    Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.
    Iyer AK; Duan Z; Amiji MM
    Mol Pharm; 2014 Aug; 11(8):2511-26. PubMed ID: 24661041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
    Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
    Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers.
    Tsouris V; Joo MK; Kim SH; Kwon IC; Won YY
    Biotechnol Adv; 2014; 32(5):1037-50. PubMed ID: 24924617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.
    Lage H
    Curr Drug Targets; 2006 Jul; 7(7):813-21. PubMed ID: 16842213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of breast cancer resistance protein mediated atypical multidrug resistance using RNA interference delivered by adenovirus.
    Li WT; Zhou GY; Wang CL; Guo CH; Song XR; Chi WL
    Chin Med J (Engl); 2005 Jul; 118(13):1123-6. PubMed ID: 16098268
    [No Abstract]   [Full Text] [Related]  

  • 19. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
    Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
    Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.